REPLIMUNE GROUP, INC. Stock Split Ratio
REPLIMUNE GROUP, INC. (REPL) had Stock Split Ratio of 10.05% as of 2018-07-09, per its 10-Q filed 2021-02-04.
Discontinued › Notes › Equity
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2021-02-04
- 2018-07-09: Stockholders' Equity Note, Stock Split, Conversion Ratio 10.05%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio |
|---|---|
| 2018-07-09 | 10.05% 10-Q · filed 2021-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |